30 April 2013 -- Commenting on the interim ruling of the General Court of the European Union preventing the European Medicines Agency (EMA) from providing documents as part of two access-to-documents requests until a final ruling is given by the Court, Steve Bates, BioIndustry Association (BIA) Chief Executive Officer, said:
"The interim ruling must not delay the timetable for introducing a modernised Clinical Trial Regulation for Europe.
"Additionally, the BIA and its members have played an active role in the five advisory groups set up to inform the agency on specific aspects of its policy on proactive publication of data from clinical trials and welcome today's publication of the final advice and looks forward to contributing to the consultation on the EMA draft policy."
For further information, please contact Robert Winder, Head of Communications, email@example.com, 020 7630 2191; mobile 07825 942 934.
EMA final advice from clinical trial advisory groups
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org